A pilot study of Abraxane (albumin-bound paclitaxel) and Temodar (temozolomide) plus Genasense (oblimersen sodium) in subjects with advanced melanoma (The ATG study).

Trial Profile

A pilot study of Abraxane (albumin-bound paclitaxel) and Temodar (temozolomide) plus Genasense (oblimersen sodium) in subjects with advanced melanoma (The ATG study).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2011

At a glance

  • Drugs Oblimersen; Paclitaxel; Temozolomide
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms ATG
  • Sponsors Genta (CEASED)
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 May 2011 Results will be presented at ASCO-2011, according to a Genta media release.
    • 27 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top